NSNina Schatz‐Siemers

Nina Schatz‐Siemers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nina Schatz‐Siemers has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Amihai Rottenstreich

    Department of Obstetrics and Gynecology, Laboratory of Blood and Vascular Biology Rockefeller University New York New York USA

    1 shared publication
  • Andrea Hernandez

    Department of Pathology, New York University School of Medicine, New York, New York

    1 shared publication
  • Debra Newman

    Department of Pathology, Versiti Blood Center of Wisconsin Blood Research Institute Milwaukee Wisconsin USA

    1 shared publication
  • Emilie Vander Haar

    Division of Maternal‐Fetal Medicine Department of Obstetrics and Gynecology Weill Cornell Medicine New York New York USA

    1 shared publication
  • Huiying Zhi

    Department of Pathology, Versiti Blood Center of Wisconsin Blood Research Institute Milwaukee Wisconsin USA

    1 shared publication
  • James B. Bussel

    Weill Cornell Medical College New York New York USA

    1 shared publication

Latest Publications

  • Open Access

    Does anti‐HPA‐1a affect birthweight in fetal and neonatal alloimmune thrombocytopenia?

    by Margaret McKelvy, Srishti Tyagi, Emilie Vander Haar, Madhavi Lakkaraja, Tim Tomy, Stacy Corke, Thea Palmer, Amihai Rottenstreich, Rick Kapur, Huiying Zhi, et al.

    Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) ensues from parental incompatibility for platelet alloantigens with maternal sensitization. HPA‐1a/1b incompatibility is the most common cause of FNAIT in Caucasians. Placental villitis and lower birthweight in FNAIT suggest anti‐HPA‐1a may have effects beyond inducing thrombocytopenia. Objectives: Does FNAIT secondary to anti‐HPA‐1a result in smaller newborns and, the corollary, does antenatal management of FNAIT increase birthweight? Study design: Birthweights of 270 FNAIT‐affected newborns from a randomized clinical trial and a NAITbabies.org survey (135 paired siblings) were compared with those of published controls and treated to untreated FNAIT‐affected siblings. Birthweights were converted to percentiles to account for gestational age, sex, and role of birth order in birth weight. Body weights of FNAIT‐affected and ‐unaffected pups in a mouse FNAIT model were analyzed. Results: Untreated siblings in both the clinical trial and NAITbabies.org cohorts were not small, compared with normal controls. However, treated siblings in both cohorts had significantly higher birthweight percentiles compared with their previous untreated affected sibling. After accounting for gestational age, sex, and birth order, increased birthweight percentile in treated compared with the untreated siblings remained significant in both cohorts. FNAIT‐affected neonatal mice had lower bodyweights than FNAIT‐unaffected pups. Conclusions: Untreated FNAIT‐affected newborns were not small; however, treatment of FNAIT‐affected pregnancies increased newborn birthweights despite corrections to account for other factors that might have influenced the results. High dose IVIG is believed to “block” FcRn and lower maternal anti‐HPA‐1a levels, and thus increase birthweights by reducing levels of maternal anti‐HPA‐1a and reducing placental villitis.


  • Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation

    by Nina Schatz‐Siemers, Tamar C Brandler, Thaira Oweity, Wei Sun, Andrea Hernandez, Pascale Levine

    Background: Hürthle cell lesions often pose diagnostic challenges, despite their common occurrence on thyroid fine‐needle aspiration cytology (FNAC). The associated molecular alterations are also not well understood. Therefore, our study aimed to delineate the molecular profile of Hürthle cell lesions classified as Bethesda Categories III or IV (atypia of undetermined significance (AUS) or suspicious for follicular neoplasm (SFN)) on FNAC and to correlate this molecular profile with surgical resection findings.Methods: This study consisted of 188 Hürthle cell lesions with indeterminate cytology and ThyroSeq® v2/v3 molecular testing results. Surgical follow‐up was available for 33 cases.Results: The majority of indeterminate Hürthle cell lesions had negative ThyroSeq® results (61%) and were benign on available surgical follow‐up. The most prevalent mutations involved the RAS gene (21%), which were associated with benign lesions, non‐invasive follicular thyroid neoplasms with papillary‐like nuclear features (NIFTP), and malignancy. The remaining mutations involved less than 18% of the cases, including PAX8/PPARG (3.7%), TSHR (3.7%), EIF1AX (2.7%), MET (2.1%), PTEN (1.6%), clonal copy number alteration (1.6%), TERT (1.1%), and 0.5% each of GNAS, PIK3CA, and TP53 mutations. On follow‐up, 45% were benign, 24% were NIFTP, and 30% were malignant. The malignant cases had different molecular alterations.Conclusion: No single molecular alteration defines cytologically indeterminate Hürthle cell lesions; the majority of cases have low‐risk or no molecular alterations and are benign on follow‐up. These findings suggest that molecular testing may be useful, but is not definitive, in determining which cases may be managed conservatively; additional studies are needed to fully determine the negative predictive value in ruling out malignancy.